Epigallocatechin gallate, an active green tea compound inhibits the Zika virus entry into host cells via binding the envelope protein

International Journal of Biological Macromolecules

Volumn 104, Issue , 2017, Pages 1046-1054

  Sharma, Nitin ^a   Murali, Aarthy ^b   Singh, Sanjeev Kumar ^b   Giri, Rajanish ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MANDI   (India)

^b ALAGAPPA UNIVERSITY   (India)

Author keywords

Envelope protein; Epigallocatechin gallate; Zika virus

Indexed keywords

EPIGALLOCATECHIN GALLATE; VIRUS ENVELOPE PROTEIN; VIRUS FUSION INHIBITOR; ANTIVIRUS AGENT; CATECHIN; LIGAND; PROTEIN BINDING;

ARTICLE; DRUG BINDING SITE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN CONFORMATION; VIRUS ENTRY; ZIKA VIRUS; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; TEA; THERMODYNAMICS;

ANTIVIRAL AGENTS; CATECHIN; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; TEA; THERMODYNAMICS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION; ZIKA VIRUS;

EID: 85021909945     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2017.06.105     Document Type: Article

References (52)

1. Wikan, N., Smith, D.R., Zika virus: history of a newly emerging arbovirus. Lancet. Infect. Dis. 16 (2016), e119–e126, 10.1016/S1473-3099(16)30010-X.
2. D'Ortenzio, E., Matheron, S., de Lamballerie, X., Hubert, B., Piorkowski, G., Maquart, M., Descamps, D., Damond, F., Yazdanpanah, Y., Leparc-Goffart, I., Evidence of sexual transmission of Zika virus. N. Engl. J. Med., 2016, 1386–1388, 10.1056/nejmc1604449.
3. Musso, D., Roche, C., Robin, E., Nhan, T., Teissier, A., Cao-Lormeau, V.-M., Potential sexual transmission of Zika virus. Emerg. Infect. Dis. 21 (2015), 359–361, 10.3201/eid2102.141363.
4. The Lancet Infectious Diseases, Zika virus at the games: is it safe?. Lancet. Infect. Dis., 16, 2016, 619, 10.1016/S1473-3099(16)30069-X.
5. Mlakar, J., Korva, M., Tul, N., Popović, M., Poljšak-Prijatelj, M., Mraz, J., Kolenc, M., Resman Rus, K., Vesnaver Vipotnik, T., Fabjan Vodušek, V., Vizjak, A., Pižem, J., Petrovec, M., Avšič Županc, T., Zika virus associated with microcephaly. N. Engl. J. Med. 374 (2016), 951–958, 10.1056/NEJMoa1600651.
6. Cao-Lormeau, V.-M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., Dub, T., Baudouin, L., Teissier, A., Larre, P., Vial, A.-L., Decam, C., Choumet, V., Halstead, S.K., Willison, H.J., Musset, L., Manuguerra, J.-C., Despres, P., Fournier, E., Mallet, H.-P., Musso, D., Fontanet, A., Neil, J., Ghawché, F., Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet (London, England) 387 (2016), 1531–1539, 10.1016/S0140-6736(16)00562-6.
7. Tang, H., Hammack, C., Ogden, S.C., Wen, Z., Qian, X., Li, Y., Yao, B., Shin, J., Zhang, F., Lee, E.M., Christian, K.M., Didier, R.A., Jin, P., Song, H., Ming, G.-L., Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell. 18 (2016), 587–590, 10.1016/j.stem.2016.02.016.
8. Maurice, J., The Zika virus public health emergency: 6 months on. Lancet (London, England) 388 (2016), 449–450, 10.1016/S0140-6736(16)31207-7.
9. Heymann, D.L., Hodgson, A., Sall, A.A., Freedman, D.O., Staples, J.E., Althabe, F., Baruah, K., Mahmud, G., Kandun, N., Vasconcelos, P.F.C., Bino, S., Menon, K.U., Zika virus and microcephaly: why is this situation a PHEIC?. Lancet (London, England) 387 (2016), 719–721, 10.1016/S0140-6736(16)00320-2.
10. Brasil, P., Pereira, J.P. Jr., Raja Gabaglia, C., Damasceno, L., Wakimoto, M., Ribeiro Nogueira, R.M., Carvalho de Sequeira, P., Machado Siqueira, A., Abreude Carvalho, L.M., Cotrimda Cunha, D., Calvet, G.A., Neves, E.S., Moreira, M.E., Rodrigues Baião, A.E., Nassarde Carvalho, P.R., Janzen, C., Valderramos, S.G., Cherry, J.D., Bispode Filippis, A.M., Nielsen-Saines, K., Zika virus infection in pregnant women in Rio de Janeiro—preliminary report. N. Engl. J. Med., 2016, 10.1056/NEJMoa1602412 (NEJMoa1602412).
11. Li, J., Chong, C.Y., Tan, N.W., Yung, C.F., Tee, N.W., Thoon, K.C., Characteristics of Zika virus disease in children: clinical, hematological, and virological findings from an outbreak in Singapore. Clin. Infect. Dis. 64 (2017), 1445–1448, 10.1093/cid/cix137.
12. Areas with Risk of Zika | Zika virus | CDC, (n.d.). https://www.cdc.gov/zika/geo/. (Accessed 11 May 2017).
13. Gould, E.A., Solomon, T., Pathogenic flaviviruses. Lancet (London, England) 371 (2008), 500–509, 10.1016/S0140-6736(08)60238-X.
14. Shi, Y., Gao, G.F., Structural biology of the Zika virus. Trends Biochem. Sci. 42 (2017), 443–456, 10.1016/j.tibs.2017.02.009.
15. Giri, R., Kumar, D., Sharma, N., Uversky, V.N., Intrinsically disordered side of the Zika virus proteome. Front. Cell. Infect. Microbiol., 6, 2016, 144, 10.3389/fcimb.2016.00144.
16. Toto, A., Giri, R., Brunori, M., Gianni, S., The mechanism of binding of the KIX domain to the mixed lineage leukemia protein and its allosteric role in the recognition of c-Myb. Protein Sci. 23 (2014), 962–969, 10.1002/pro.2480.
17. Toto, A., Camilloni, C., Giri, R., Brunori, M., Vendruscolo, M., Gianni, S., Molecular recognition by templated folding of an intrinsically disordered protein. Sci. Rep., 6, 2016, 21994, 10.1038/srep21994.
18. Kumar, D., Sharma, N., Giri, R., Therapeutic interventions of cancers using intrinsically disordered proteins as drug targets: c-Myc as model system. Cancer Inf., 16, 2017, 10.1177/1176935117699408 (1176935117699408).
19. Dolan, P.T., Roth, A.P., Xue, B., Sun, R., Dunker, A.K., Uversky, V.N., LaCount, D.J., Intrinsic disorder mediates hepatitis C virus core-host cell protein interactions. Protein Sci. 24 (2015), 221–235, 10.1002/pro.2608.
20. Khrustalev, V.V., Khrustaleva, T.A., Sharma, N., Giri, R., Mutational pressure in Zika virus: local ADAR-editing areas associated with pauses in translation and replication. Front. Cell. Infect. Microbiol., 7, 2017, 44, 10.3389/fcimb.2017.00044.
21. Dai, L., Song, J., Lu, X., Deng, Y.-Q., Musyoki, A.M., Cheng, H., Zhang, Y., Yuan, Y., Song, H., Haywood, J., Xiao, H., Yan, J., Shi, Y., Qin, C.-F., Qi, J., Gao, G.F., Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microb. 19 (2016), 696–704, 10.1016/j.chom.2016.04.013.
22. Harrison, S.C., Viral membrane fusion. Nat. Struct. Mol. Biol. 15 (2008), 690–698, 10.1038/nsmb.1456.
23. Kielian, M., Rey, F.A., Virus membrane-fusion proteins: more than one way to make a hairpin. Nat. Rev. Microbiol. 4 (2006), 67–76, 10.1038/nrmicro1326.
24. Modis, Y., Ogata, S., Clements, D., Harrison, S.C., Structure of the dengue virus envelope protein after membrane fusion. Nature 427 (2004), 313–319, 10.1038/nature02165.
25. Gianni, S., Morrone, A., Giri, R., Brunori, M., A folding-after-binding mechanism describes the recognition between the transactivation domain of c-Myb and the KIX domain of the CREB-binding protein. Biochem. Biophys. Res. Commun. 428 (2012), 205–209, 10.1016/j.bbrc.2012.09.112.
26. Giri, R., Morrone, A., Toto, A., Brunori, M., Gianni, S., Structure of the transition state for the binding of c-Myb and KIX highlights an unexpected order for a disordered system. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 14942–14947, 10.1073/pnas.1307337110.
27. Carneiro, B.M., Batista, M.N., Braga, A.C.S., Nogueira, M.L., Rahal, P., The green tea molecule EGCG inhibits Zika virus entry. Virology 496 (2016), 215–218, 10.1016/j.virol.2016.06.012.
28. Sherman, Woody, Day, Tyler, Jacobson, Matthew P., Friesner, Richard A., Farid, Ramy, Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem., 2005, 10.1021/JM050540C.
29. Desmond-version 3.1. New York, NY: Schrodinger, LLC, 2012.
30. Abdul Samad, F., Suliman, B.A., Basha, S.H., Manivasagam, T., Essa, M.M., Reddy, E.S., A comprehensive In silico analysis on the structural and functional impact of SNPs in the congenital heart defects associated with NKX2-5 gene—a molecular dynamic simulation approach. PLoS One, 11, 2016, e0153999, 10.1371/journal.pone.0153999.
31. Jorgensen, William L., Maxwell, David S., Tirado-Rives, J., Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118:45 (1996), 11225–11236, 10.1021/JA9621760.
32. Chavan, S.G., Deobagkar, D.D., Hruby, V., Preissner, R., Klein, M., Abdul-Hay, S., An In silico insight into novel therapeutic interaction of LTNF peptide-LT10 and design of structure based peptidomimetics for putative anti-diabetic activity. PLoS One, 10, 2015, e0121860, 10.1371/journal.pone.0121860.
33. Gupta, S., Yadav, S., Suryanarayanan, V., Singh, S.K., Saxena, J.K., Investigating the folding pathway and substrate induced conformational changes in B. malayi Guanylate kinase. Int. J. Biol. Macromol. 94 (2017), 621–633, 10.1016/j.ijbiomac.2016.10.008.
34. Suryanarayanan, V., Singh, S.K., Assessment of dual inhibition property of newly discovered inhibitors against PCAF and GCN5 through in silico screening, molecular dynamics simulation and DFT approach. J. Recept. Signal Transduct. 35 (2015), 370–380, 10.3109/10799893.2014.956756.
35. Tripathi, S.K., Singh, S.K., Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction MESP and MD simulation. Mol. Biosyst. 10 (2014), 2189–2201, 10.1039/c4mb00077c.
36. Shukla, R., Shukla, H., Sonkar, A., Pandey, T., Tripathi, T., Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of mycobacterium tuberculosis isocitrate lyase. J. Biomol. Struct. Dyn., 2017, 1–13, 10.1080/07391102.2017.1341337.
37. Zheng, Y., Sánchez-San Martín, C., Qin, Z., Kielian, M., The domain I-domain III linker plays an important role in the fusogenic conformational change of the alphavirus membrane fusion protein. J. Virol. 85 (2011), 6334–6342, 10.1128/JVI.00596-11.
38. Kielian, M., Class II virus membrane fusion proteins. Virology 344 (2006), 38–47, 10.1016/j.virol.2005.09.036.
39. Shukla, H., Shukla, R., Sonkar, A., Pandey, T., Tripathi, T., Distant Phe345 mutation compromises the stability and activity of Mycobacterium tuberculosis isocitrate lyase by modulating its structural flexibility. Sci. Rep., 7, 2017, 1058, 10.1038/s41598-017-01235-z.
40. Wang, Q.-Y., Shi, P.-Y., Flavivirus entry inhibitors. ACS Infect. Dis. 1 (2015), 428–434, 10.1021/acsinfecdis.5b00066.
41. Singh, B.K., Sarkar, N., Jagannadham, M.V., Dubey, V.K., Modeled structure of trypanothione reductase of Leishmania infantum. BMB Rep. 41 (2008), 444–447 http://www.bmbreports.org/journal/view.html?uid=1003&vmd=Full. (Accessed 23 June 2017).
42. Saudagar, P., Saha, P., Saikia, A.K., Dubey, V.K., Molecular mechanism underlying antileishmanial effect of oxabicyclo[3.3.1]nonanones: inhibition of key redox enzymes of the pathogen. Eur. J. Pharm. Biopharm. 85 (2013), 569–577, 10.1016/j.ejpb.2013.08.014.
43. Matthews, T., Salgo, M., Greenberg, M., Chung, J., DeMasi, R., Bolognesi, D., Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3 (2004), 215–225, 10.1038/nrd1331.
44. Esté, J.A., Telenti, A., HIV. entry inhibitors. Lancet (London, England) 370 (2007), 81–88, 10.1016/S0140-6736(07)61052-6.
45. Steinmann, J., Buer, J., Pietschmann, T., Steinmann, E., Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol. 168 (2013), 1059–1073, 10.1111/bph.12009.
46. Kostyuchenko, V.A., Lim, E.X.Y., Zhang, S., Fibriansah, G., Ng, T.-S., Ooi, J.S.G., Shi, J., Lok, S.-M., Structure of the thermally stable Zika virus. Nature 7603 (2016), 425–428, 10.1038/nature17994.
47. Liao, M., Kielian, M., Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J. Cell Biol. 171 (2005), 111–120, 10.1083/jcb.200507075.
48. Stiasny, K., Kössl, C., Lepault, J., Rey, F.A., Heinz, F.X., Characterization of a structural intermediate of flavivirus membrane fusion. PLoS Pathog., 3, 2007, e20, 10.1371/journal.ppat.0030020.
49. Halegoua-De Marzio, D., Kraft, W.K., Daskalakis, C., Ying, X., Hawke, R.L., Navarro, V.J., Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract. Clin. Ther., 34, 2012, 10.1016/j.clinthera.2012.10.009 2279–2285e1.
50. Qian, X.-J., Zhu, Y.-Z., Zhao, P., Qi, Z.-T., Entry inhibitors: new advances in HCV treatment. Emerg. Microb. Infect., 5(1), 2016, e3, 10.1038/emi.2016.3.
51. Khan, N., Mukhtar, H., Tea and health: studies in humans. Curr. Pharm. Des. 19 (2013), 6141–6147 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4055352&tool=pmcentrez&rendertype=abstract. (Accessed 13 August 2016).
52. Isbrucker, R.A., Edwards, J.A., Wolz, E., Davidovich, A., Bausch, J., Safety studies on epigallocatechin gallate (EGCG) preparations. Part 3: teratogenicity and reproductive toxicity studies in rats. Food Chem. Toxicol. 44 (2006), 651–661, 10.1016/j.fct.2005.11.002.